Evidence map›Paper›PMID 34309456›Full record

ReviewJournal of enzyme inhibition and medicinal chemistry2021

The role of mTOR in age-related diseases.

Zofia Chrienova, Eugenie Nepovimova, Kamil Kuca

Abstract readReview
In one paragraph

Review in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Kimchi ProbioticJournal of microbiology and biotechnology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. New Insight onMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zofia ChrienovaDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czechia.
Eugenie NepovimovaDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czechia.ORCID https://orcid.org/0000-0003-0281-246X
Kamil KucaDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czechia.ORCID https://orcid.org/0000-0001-9664-1109

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ageing population is becoming a significant socio-economic issue. To address the expanding health gap, it is important to deepen our understanding of the mechanisms underlying ageing in various organisms at the single-cell level. The discovery of the antifungal, immunosuppressive, and anticancer drug rapamycin, which possesses the ability to extend the lifespan of several species, has prompted extensive research in the areas of cell metabolic regulation, development, and senescence. At the centre of this research is the mTOR pathway, with key roles in cell growth, proteosynthesis, ribosomal biogenesis, transcriptional regulation, glucose and lipid metabolism, and autophagy. Recently, it has become obvious that mTOR dysregulation is involved in several age-related diseases, such as cancer, neurodegenerative diseases, and type 2 diabetes mellitus. Additionally, mTOR hyperactivation affects the process of ageing per se. In this review, we provide an overview of recent insights into the mTOR signalling pathway, including its regulation and its influence on various hallmarks of ageing at the cellular level.

Indexed as

Age FactorsAnimalsHumansNeoplasmsNeurodegenerative DiseasesSignal TransductionTOR Serine-Threonine KinasesTOR Serine-Threonine KinasesAgeingage-related diseasemTORC1mTORC2rapamycin

Identifiers

PMID34309456
PMCPMC8317948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.